Optimizing Hospital Infection Control: The Role of Mathematical Modeling

Grants

Funding Acknowledgements

Financial support. T.N.D. was supported by a Monash Graduate Scholarship and a Monash International Postgraduate Research Scholarship. E.S.M. has received financial support from a National Health and Medical Research Council Career Development Fellowship.Potential conflicts of interest. D.C.M.K. reports having sat on advisory boards for Pfizer and receiving financial/travel support (unrelated to the current work) from Pfizer, Roche, Merck, Novartis, and Gilead Sciences. C.M.J.K. reports having undertaken collaborative research projects unrelated to the current work with Roche, Pfizer, CSL, and d3 Medicine. All other authors report no conflicts of interest relevant to this article. All authors submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest, and the conflicts that the editors consider relevant to this article are disclosed here.